Σφακιανάκης Αλέξανδρος
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5 Άγιος Νικόλαος
Κρήτη 72100
00302841026182
00306932607174
alsfakia@gmail.com

Αρχειοθήκη ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader

Η λίστα ιστολογίων μου

Τρίτη 15 Νοεμβρίου 2022

A Prospective Study of BurstDRTM Spinal Cord Stimulation for non‐Operated Discogenic Low Back Pain

alexandrossfakianakis shared this article with you from Inoreader

Abstract

Introduction

Chronic discogenic low back pain (CD-LBP) is caused by degeneration of the disc due to trauma to the annulus or by unprovoked degeneration, resulting in chronic pain. Spinal cord stimulation (SCS) employing the BurstDRTM waveform has been shown to be an effective treatment in a variety of chronic pain conditions. The aim of this prospective case study was to determine the effect of BurstDRTM SCS on pain relief, disability, and patient satisfaction in a population with CD-LBP.

Methods

17 subjects with CD-LBP received a SCS trial with BurstDRTM stimulation. Patients with >50% pain relief after a trial period of 2 weeks were permanently implanted (n=15). Patients then rated LBP and leg pain using the numeric rating scale (NRS), Oswestery disability index (ODI), patient global impression of change (PGIC), EQ-5D quality of life and paindetect for neuropathic pain at baseline following trial, 3, 6 and 12 months after permanent implantation.

Results

Treatment with BurstDRTM SCS resulted in significant reduction of LBP as the NRS was reduced from 71.7± 7.3 at baseline to 42.5 ± 18.1 at 12 months. Average pain relief at 12 months was 42.5%. In patients with leg pain (n=8), pain was significantly reduced from 66.9 ± 8.2, to 11.7 ± 10.4 at 12 months. PainDETECT scores for neuropathic pain significantly reduced from 18.9 ± 4.8 at baseline, and 14.8 ± 3.2 at 12 months. Baseline ODI score significantly reduced from 41.2 ± 12.8, to 25.8 ± 8.6 at 12 months. PGIC scores remained low from 2.6 ± 1.6 at 3 months, 2.5 ± 1.0 at 6 months and 2.5 ± 1.3 at 12 months. EQ-5D-5L rates remained constant from baseline 56.10 ± 23.9 to 68.6 ± 12.9 at 12 months.

Conclusion

BurstDRTM SCS resulted in significant reduction of back pain, leg pain and quality of life in patients with CD-LBP and decreased the level of disability and generated positive patient satisfaction scores..

View on Web

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου